X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dishman Pharma with Divis Laboratories - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs DIVIS LABORATORIES - Comparison Results

DISHMAN PHARMA    Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

DIVIS LABORATORIES 
   Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DISHMAN PHARMA DIVIS LABORATORIES DISHMAN PHARMA/
DIVIS LABORATORIES
 
P/E (TTM) x 25.1 18.1 138.9% View Chart
P/BV x 3.3 3.9 85.6% View Chart
Dividend Yield % 0.7 1.6 42.0%  

Financials

 DISHMAN PHARMA   DIVIS LABORATORIES
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
DIVIS LABORATORIES
Mar-16
DISHMAN PHARMA/
DIVIS LABORATORIES
5-Yr Chart
Click to enlarge
High Rs3742,484 15.1%   
Low Rs129918 14.0%   
Sales per share (Unadj.) Rs197.8142.3 139.0%  
Earnings per share (Unadj.) Rs21.241.9 50.6%  
Cash flow per share (Unadj.) Rs34.746.3 74.9%  
Dividends per share (Unadj.) Rs2.0010.00 20.0%  
Dividend yield (eoy) %0.80.6 135.2%  
Book value per share (Unadj.) Rs179.9161.5 111.4%  
Shares outstanding (eoy) m80.69265.47 30.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.312.0 10.6%   
Avg P/E ratio x11.940.6 29.2%  
P/CF ratio (eoy) x7.236.7 19.7%  
Price / Book Value ratio x1.410.5 13.3%  
Dividend payout %9.423.9 39.5%   
Avg Mkt Cap Rs m20,306451,525 4.5%   
No. of employees `0000.83.7 22.4%   
Total wages/salary Rs m5,3553,649 146.7%   
Avg. sales/employee Rs Th19,252.710,184.4 189.0%   
Avg. wages/employee Rs Th6,459.5984.1 656.4%   
Avg. net profit/employee Rs Th2,064.12,998.5 68.8%   
INCOME DATA
Net Sales Rs m15,96137,764 42.3%  
Other income Rs m265848 31.3%   
Total revenues Rs m16,22638,612 42.0%   
Gross profit Rs m4,10314,138 29.0%  
Depreciation Rs m1,0911,182 92.3%   
Interest Rs m94423 4,070.7%   
Profit before tax Rs m2,33413,781 16.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m10-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m6242,662 23.4%   
Profit after tax Rs m1,71111,119 15.4%  
Gross profit margin %25.737.4 68.7%  
Effective tax rate %26.719.3 138.3%   
Net profit margin %10.729.4 36.4%  
BALANCE SHEET DATA
Current assets Rs m11,01830,947 35.6%   
Current liabilities Rs m9,5175,195 183.2%   
Net working cap to sales %9.468.2 13.8%  
Current ratio x1.26.0 19.4%  
Inventory Days Days110117 94.6%  
Debtors Days Days3585 40.9%  
Net fixed assets Rs m16,30417,027 95.8%   
Share capital Rs m161531 30.4%   
"Free" reserves Rs m12,90742,341 30.5%   
Net worth Rs m14,51642,877 33.9%   
Long term debt Rs m4,1895 89,136.2%   
Total assets Rs m29,80549,684 60.0%  
Interest coverage x3.5595.0 0.6%   
Debt to equity ratio x0.30 263,297.3%  
Sales to assets ratio x0.50.8 70.5%   
Return on assets %8.922.4 39.7%  
Return on equity %11.825.9 45.5%  
Return on capital %17.532.2 54.5%  
Exports to sales %24.885.3 29.1%   
Imports to sales %3.722.9 16.3%   
Exports (fob) Rs m3,95632,198 12.3%   
Imports (cif) Rs m5968,654 6.9%   
Fx inflow Rs m4,95232,270 15.3%   
Fx outflow Rs m6978,775 7.9%   
Net fx Rs m4,25523,496 18.1%   
CASH FLOW
From Operations Rs m2,78610,379 26.8%  
From Investments Rs m-1,529-4,135 37.0%  
From Financial Activity Rs m-941-6,241 15.1%  
Net Cashflow Rs m3163 9,587.9%  

Share Holding

Indian Promoters % 61.4 52.0 118.1%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 3.7 11.8 31.4%  
FIIs % 12.7 19.0 66.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.1 17.2 128.5%  
Shareholders   46,261 31,796 145.5%  
Pledged promoter(s) holding % 35.8 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DISHMAN PHARMA With:   PLETHICO PHARMA  ELDER PHARMA  ALEMBIC LTD  ALKEM LABORATORIES  CADILA HEALTHCARE  

Compare DISHMAN PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades Marginally Higher; Pharma Stocks Among Top Gainers(01:30 pm)

After opening the day in green, share markets in India witnessed choppy trades and are presently trading marginally above the dotted line.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

The Most Important Innovation in Finance Since Gold Coins(Vivek Kaul's Diary)

Aug 10, 2017

Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

5 Steps To Become Financially Independent(Outside View)

Aug 16, 2017

Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA - CADILA HEALTHCARE COMPARISON

COMPARE DISHMAN PHARMA WITH

MARKET STATS